New perspectives and interdisciplinary insights on the benefits of MR antagonism in CKD and T2D

Chair: Jiten Vora (UK)

18:30–18:35

Welcome and introductions

Jiten Vora (UK)

18:35–18:45

Addressing unmet needs in CKD and T2D with nonsteroidal MR antagonists

Roland Schmieder (GER)

18:45–19:00

MR antagonism confers benefits irrespective of anti-diabetic agents or metabolic status: Insights from FIDELIO-DKD

Paola Fioretto (ITA)

19:00–19:15

FIGARO-DKD: Expanding the benefit of MR antagonism in CKD and T2D

Samy Hadjadj (FRA)

19:15–19:25

Q&A

All faculty

19:25–19:30

Summary and close

Jiten Vora (UK)